Norges Bank’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $164M | Buy |
+973,880
| New | +$144M | 0.02% | 600 |
|
|
2026
Q1 | – | Sell |
-1,146,896
| Closed | -$163M | – | 893 |
|
|
2025
Q4 | $163M | Buy |
+1,146,896
| New | +$166M | 0.02% | 578 |
|
|
2025
Q3 | – | Sell |
-972,856
| Closed | -$122M | – | 998 |
|
|
2025
Q2 | $122M | Sell |
972,856
-26,965
| -3% | -$3.09M | 0.02% | 632 |
|
|
2025
Q1 | $111M | Buy |
999,821
+674,526
| +207% | +$85.4M | 0.02% | 635 |
|
|
2024
Q4 | $44.4M | Sell |
325,295
-25,769
| -7% | -$3.19M | 0.01% | 1008 |
|
|
2024
Q3 | $40.4M | Sell |
351,064
-98,501
| -22% | -$13.5M | 0.01% | 1045 |
|
|
2024
Q2 | $61.9M | Buy |
449,565
+24,349
| +6% | +$3.34M | 0.01% | 821 |
|
|
2024
Q1 | $58.6M | Buy |
425,216
+154,034
| +57% | +$21M | 0.01% | 866 |
|
|
2023
Q4 | $35.7M | Buy |
271,182
+191,277
| +239% | +$22M | 0.01% | 1062 |
|
|
2023
Q3 | $8.99M | Buy |
79,905
+25,578
| +47% | +$2.69M | ﹤0.01% | 1515 |
|
|
2023
Q2 | $5.12M | Sell |
54,327
-741,083
| -93% | -$72.4M | ﹤0.01% | 1712 |
|
|
2023
Q1 | $80.5M | Sell |
795,410
-140,505
| -15% | -$14.6M | 0.02% | 615 |
|
|
2022
Q4 | $112M | Buy |
935,915
+62,242
| +7% | +$7.29M | 0.03% | 506 |
|
|
2022
Q3 | $92.8M | Buy |
873,673
+18,731
| +2% | +$1.9M | 0.02% | 529 |
|
|
2022
Q2 | $83.3M | Buy |
854,942
+23,883
| +3% | +$2.2M | 0.02% | 575 |
|
|
2022
Q1 | $77.9M | Buy |
831,059
+62,643
| +8% | +$5.31M | 0.02% | 669 |
|
|
2021
Q4 | $65.4M | Buy |
768,416
+3,997
| +0.5% | +$368K | 0.01% | 801 |
|
|
2021
Q3 | $73.3M | Buy |
764,419
+31,217
| +4% | +$2.95M | 0.02% | 751 |
|
|
2021
Q2 | $71.4M | Buy |
733,202
+47,600
| +7% | +$4.56M | 0.02% | 780 |
|
|
2021
Q1 | $66.7M | Sell |
685,602
-21,800
| -3% | -$2.29M | 0.02% | 814 |
|
|
2020
Q4 | $67.8M | Sell |
707,402
-31,949
| -4% | -$3.09M | 0.02% | 774 |
|
|
2020
Q3 | $71.1M | Sell |
739,351
-13,200
| -2% | -$1.53M | 0.02% | 674 |
|
|
2020
Q2 | $91.8M | Sell |
752,551
-38,284
| -5% | -$4.23M | 0.03% | 537 |
|
|
2020
Q1 | $68.4M | Buy |
790,835
+4,921
| +0.6% | +$482K | 0.02% | 568 |
|
|
2019
Q4 | $84.5M | Sell |
785,914
-70,697
| -8% | -$7.4M | 0.02% | 618 |
|
|
2019
Q3 | $77.2M | Hold |
856,611
| – | – | 0.02% | 625 |
|
|
2019
Q2 | $72.3M | Hold |
856,611
| – | – | 0.02% | 670 |
|
|
2019
Q1 | $75.5M | Hold |
856,611
| – | – | 0.02% | 611 |
|
|
2018
Q4 | $61.2M | Hold |
856,611
| – | – | 0.02% | 629 |
|
|
2018
Q3 | $105M | Hold |
856,611
| – | – | 0.03% | 476 |
|
|
2018
Q2 | $84.2M | Sell |
856,611
-19,657
| -2% | -$1.76M | 0.03% | 553 |
|
|
2018
Q1 | $72.7M | Hold |
876,268
| – | – | 0.03% | 601 |
|
|
2017
Q4 | $68M | Hold |
876,268
| – | – | 0.02% | 631 |
|
|
2017
Q3 | $53.7M | Hold |
876,268
| – | – | 0.02% | 733 |
|
|
2017
Q2 | $40.3M | Buy |
876,268
+80,974
| +10% | +$3.93M | 0.02% | 895 |
|
|
2017
Q1 | $34.4M | Sell |
795,294
-103,360
| -12% | -$4.43M | 0.01% | 971 |
|
|
2016
Q4 | $34.8M | Hold |
898,654
| – | – | 0.02% | 907 |
|
|
2016
Q3 | $43.5M | Hold |
898,654
| – | – | 0.02% | 708 |
|
|
2016
Q2 | $40.8M | Buy |
898,654
+181,241
| +25% | +$8.34M | 0.02% | 739 |
|
|
2016
Q1 | $28.4M | Sell |
717,413
-31,894
| -4% | -$1.27M | 0.01% | 941 |
|
|
2015
Q4 | $42.4M | Buy |
749,307
+33,919
| +5% | +$1.72M | 0.02% | 689 |
|
|
2015
Q3 | $28.5M | Buy |
715,388
+247,402
| +53% | +$12M | 0.01% | 901 |
|
|
2015
Q2 | $22.4M | Buy |
467,986
+296,151
| +172% | +$12.6M | 0.01% | 1142 |
|
|
2015
Q1 | $6.82M | Buy |
+171,835
| New | +$6.15M | ﹤0.01% | 1806 |
|
Other funds holding NBIX
Norges Bank's NBIX Position: Q2 2026 in Review
Norges Bank opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 973,880 shares worth $164M. The stake represents 0.02% of the portfolio and ranks #600 among its holdings. This is a return to the name: Norges Bank previously reported a position in NBIX as recently as Q4 2025.
Norges Bank first reported a position in NBIX in Q1 2015 and has held it in 44 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Norges Bank held 973,880 shares of Neurocrine Biosciences worth $164M as of Q2 2026.
- Neurocrine Biosciences was a new Norges Bank position in Q2 2026.
- Neurocrine Biosciences made up 0.02% of Norges Bank's portfolio in Q2 2026, its #600 holding.
- Norges Bank first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 44 quarters since.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Norges Bank's 13F filing for Q2 2026, filed 12 Aug 2026.